ADVERTISEMENT
Reviewing the Latest Research on Multiple Myeloma
J Clin Pathways. 2022;8;(2):30-32.
Isatuximab Added to Carfilzomib and Dexamethasone Extends PFS in Relapsed MM
The addition of isatuximab to carfilzomib and dexamethasone significantly improves PFS and depth of response in patients with relapsed MM, according to results from the IKEMA trial.
Belantamab Mafodotin Cost-Effective for Relapsed/Refractory MM
Study findings suggest that belantamab mafodotin is associated with lower costs and increased quality-adjusted life years compared to selinexor plus dexamethasone for patients with relapsed/refractory MM.
Cost-Effectiveness of Daratumumab or Bortezomib Added to Lenalidomide Plus Dexamethasone in Newly Diagnosed MM
Neither daratumumab nor bortezomib added to lenalidomide plus dexamethasone are cost-effective vs lenalidomide and dexamethasone alone for patients with newly diagnosed MM, according to a recent study.
Isatuximab Added to Pomalidomide and Dexamethasone Extends OS in Relapsed and Refractory MM
Study findings show the addition of isatuximab to pomalidomide and dexamethasone extended OS compared to pomalidomide and dexamethasone in lenalidomide-refractory and proteasome inhibitor-refractory or relapsed MM.
